BCM
ALXO icon

Bourgeon Capital Management’s ALX Oncology ALXO Stock Holding History

Bourgeon Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,570
Closed -$218K – 110
2024
Q1 		$218K Hold
19,570
– – 0.04% 105
2023
Q4 		$291K Hold
19,570
– – 0.06% 92
2023
Q3 		$93.9K Hold
19,570
– – 0.02% 122
2023
Q2 		$147K Hold
19,570
– – 0.03% 110
2023
Q1 		$88.5K Hold
19,570
– – 0.02% 121
2022
Q4 		$221K Hold
19,570
– – 0.05% 89
2022
Q3 		$187K Hold
19,570
– – 0.05% 89
2022
Q2 		$158K Hold
19,570
– – 0.04% 99
2022
Q1 		$331K Hold
19,570
– – 0.07% 80
2021
Q4 		$421K Hold
19,570
– – 0.09% 80
2021
Q3 		$1.45M Hold
19,570
– – 0.31% 53
2021
Q2 		$1.07M Hold
19,570
– – 0.23% 65
2021
Q1 		$2.15M Buy
+19,570
New +$1.54M 0.48% 50

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Bourgeon Capital Management's ALXO Position: Q2 2024 in Review

Bourgeon Capital Management sold out of ALX Oncology (ALXO) in Q2 2024, closing a stake of 19,570 shares — an estimated $218K sold.

Bourgeon Capital Management first reported a position in ALXO in Q1 2021 and held it in 13 quarters. The position peaked at $2.15M in Q1 2021. 111 funds tracked by Wall St. Rank hold ALXO as of Q2 2024.

  • Bourgeon Capital Management reported no remaining ALX Oncology position as of Q2 2024 after selling out during the quarter.
  • Bourgeon Capital Management sold 19,570 ALX Oncology shares in Q2 2024, an estimated $218K.
  • Bourgeon Capital Management first reported a position in ALX Oncology in Q1 2021 and held it in 13 quarters.
  • Bourgeon Capital Management's ALX Oncology position peaked at $2.15M in Q1 2021.
  • 111 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2024.

Based on Bourgeon Capital Management's 13F filing for Q2 2024, filed 11 Jul 2024.